Norgine's CEO Janneke van der Kamp has said other portfolio-boosting deals could be on the way. Netherlands-based pharma group Norgine has expanded its rare disease portfolio with the acquisition of ...
Theravia was formed through the merger of Addmedica and CTRS Theravia has recorded over €50 million in annual revenues Norgine is a pharmaceutical and consumer healthcare company Mérieux Equity ...
Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines ...
PARIS, Aug. 14, 2025 /PRNewswire/ -- Norgine today announced the successful completion of the acquisition of Theravia, an international pharmaceutical company specialising in therapies for patients ...
The drug inhibits progression of epidermolysis bullosa in skin. Recessive dystrophic pidermolysis bullosa (RDEB) leads to excessive deposition of fibrosis (COL I) in the skin in response to skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results